Literature DB >> 11714794

Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG.

C A Guyre1, T Keler, S L Swink, L A Vitale, R F Graziano, M W Fanger.   

Abstract

The high-affinity IgG receptor, FcgammaRI (CD64), is constitutively expressed exclusively on professional APCs. Human FcgammaRI binds monomeric IgG with high affinity and is, therefore, saturated in vivo. The binding of IgG to FcgammaRI causes receptor recycling, while Abs that cross-link FcgammaRI cause rapid down-modulation of surface FcgammaRI. Because studies performed in the absence of ligand may not be representative of FcgammaRI modulation in vivo, we investigated the ability of FcgammaRI-cross-linking Abs and non-cross-linking derivatives to modulate FcgammaRI in the presence and absence of ligand. In the absence of ligand mAb H22 and wH22xeGFP, an enhanced green fluorescent protein (eGFP)-labeled fusion protein of H22, cross-linked and rapidly down-modulated surface FcgammaRI on the human myeloid cell line, U937, and its high FcgammaRI-expressing subclone, 10.6. This effect was dependent on the concentration of fusion protein and the level of FcgammaRI expression and correlated with internalization of both wH22xeGFP and FcgammaRI, itself, as assessed by confocal microscopy. A single-chain Fv version, sFv22xeGFP, which does not cross-link FcgammaRI, was unable to modulate FcgammaRI in the absence of IgG. However, if ligand was present, treatment with either monovalent or cross-linking fusion protein led to intracellular receptor accumulation. These findings suggest at least two alternate mechanisms of internalization that are influenced by ligand and demonstrate the physiologic potential of FcgammaRI to transport a large antigenic load into APCs for processing. These studies may lead to the development of better FcgammaRI-targeted vaccines, as well as therapies to down-modulate FcR involved in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714794     DOI: 10.4049/jimmunol.167.11.6303

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Antigenic modulation and rituximab resistance.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

2.  Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?

Authors:  G P Sandilands; M Wilson; C Huser; L Jolly; W A Sands; C McSharry
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

3.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

4.  Targeting allergen to FcgammaRI reveals a novel T(H)2 regulatory pathway linked to thymic stromal lymphopoietin receptor.

Authors:  Kathryn E Hulse; Amanda J Reefer; Victor H Engelhard; James T Patrie; Steven F Ziegler; Martin D Chapman; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

Review 5.  Targeting allergen to Fc gammaRI: a strategy to treat allergic disease?

Authors:  Kathryn E Hulse; Judith A Woodfolk
Journal:  Curr Opin Allergy Clin Immunol       Date:  2008-12

6.  Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen.

Authors:  Bibiana V Iglesias; Constantine Bitsaktsis; Giang Pham; James R Drake; Karsten R O Hazlett; Kristen Porter; Edmund J Gosselin
Journal:  Immunol Cell Biol       Date:  2012-12-18       Impact factor: 5.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.